Romiplostim

證據等級: L5

預測適應症: 10 個

Romiplostim: From Chronic Immune Thrombocytopenia to Primary Release Disorder of Platelets

One-Sentence Summary

Romiplostim is a thrombopoietin (TPO) receptor agonist whose established use is chronic immune thrombocytopenia (ITP). TxGNN's highest-scoring signal points to Primary Release Disorder of Platelets as a candidate new indication, but this rests on only 1 indirectly related clinical trial and 2 mechanistic review articles — the model itself flags the mechanistic link as weak and indirect.

Quick Overview

Item	Content
Original Indication	Chronic Immune Thrombocytopenia (ITP) — noted in evidence rationale text; not confirmed via Taiwan regulatory filing (no license record exists)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	99.9998% (score rank #3 among all TxGNN outputs)
Evidence Level	L4
Taiwan Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold (evidence-pack label: "Research Question")

Why is This Prediction Reasonable?

Detailed MOA data for romiplostim is not yet available in DrugBank (flagged as data gap DG002). Based on information embedded in the evidence pack, romiplostim is a TPO receptor agonist that stimulates megakaryocyte proliferation and differentiation, thereby increasing platelet production. Its efficacy in chronic ITP — a disease of accelerated platelet destruction and impaired thrombopoiesis — is well established.

Primary release disorder of platelets, however, is a defect in platelet release/degranulation function, not in platelet count or production rate. The evidence pack's own mechanistic assessment states this directly: romiplostim's pathway can raise the number of platelets produced, but it cannot correct a release/degranulation defect. The link to ITP biology is therefore only partial — the two conditions share downstream platelet biology but not the specific dysfunction romiplostim's mechanism addresses. This is why the evidence level is capped at L4 (mechanism/observational only) despite the very high raw TxGNN score.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03820960	N/A	Completed	10,039	Large ITP registry study on thrombosis risk factors; does not test romiplostim as an intervention for this indication (relevance grade C)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23594368	2013	Review	British Journal of Haematology	Overview of megakaryocytopoiesis/thrombopoiesis biology; TPO as primary growth factor for the megakaryocyte lineage
25682608	2015	Review/Mechanistic	Haematologica	Antiplatelet autoantibodies in ITP inhibit proplatelet formation and impair platelet production in vitro

Taiwan Market Information

Romiplostim currently holds no marketing authorization in Taiwan (0 licenses on file). No approved indication text, product name, or dosage form data is available from the regulatory dataset.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Data Gap Alert: TFDA label warnings/contraindications have not yet been obtained (DG001, severity Blocking) — this must be resolved before any Stage 1 (S1) safety assessment can proceed. No drug-drug interaction records were found in the current query.

Other Predicted Indications at a Glance

This evidence pack scored romiplostim against 10 candidate indications. For context, the full landscape:

Rank	Disease	TxGNN Score	Evidence Level	Recommendation
1	Primary release disorder of platelets	99.9998%	L4	Research Question
2	Pseudo-von Willebrand disease	99.9998%	L5	Hold
3	Glanzmann thrombasthenia	99.9995%	L5	Hold
4	Fetal/neonatal alloimmune thrombocytopenia	99.99%	L4	Research Question
5	Scott syndrome	99.97%	L5	Hold
6	Hemorrhagic disorder (constitutional thrombocytopenia)	99.95%	L5	Hold
7	Bleeding diathesis (collagen receptor defect)	99.95%	L4	Hold
8	Platelet-type bleeding disorder	99.93%	L1	Proceed with Guardrails
9	Autosomal dominant macrothrombocytopenia	99.88%	L3	Research Question
10	Ehlers-Danlos syndrome, fibronectinemic type	99.85%	L5	Hold

Note: Rank 8 ("platelet-type bleeding disorder") is backed by multiple completed Phase 3/4 trials (e.g. NCT03362177 RECITE, NCT05492409) — but its own rationale states this cluster "essentially corresponds to romiplostim's core approved use (chronic ITP and related thrombocytopenia)." It is best read as a validation signal confirming model accuracy, not a novel repurposing opportunity. Ranks 2, 3, 5, 6, 10 have zero clinical trial or literature support and rest on TxGNN score alone.

Conclusion and Next Steps

Decision: Hold

Rationale: The lead prediction (primary release disorder of platelets) has a self-identified weak, indirect mechanistic link, and its only clinical trial evidence does not test romiplostim as an intervention in this population. No genuinely novel candidate in this pack reaches L1/L2 evidence — the one indication with strong trial support (rank 8) largely overlaps with romiplostim's known indication rather than representing new territory.

To proceed, the following is needed:

Resolve DG001 (TFDA label warnings/contraindications) — currently blocking any S1 safety evaluation
Resolve DG002 (confirmed MOA from DrugBank API) to strengthen mechanistic-link analysis
Confirm original approved indication via verified Taiwan regulatory filing (currently 0 licenses on record)
If pursuing primary release disorder of platelets specifically: a dedicated interventional study in confirmed platelet-release-defect patients, since existing evidence is an unrelated ITP registry and general mechanism reviews
Separately evaluate rank 8 (platelet-type bleeding disorder) as a line-extension/label-confirmation case rather than a new-indication repurposing candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.